Company News

Metabolon Launches Peak Science Grant Program to Advance Breakthrough Metabolomics Research

Quarterly grant program provides researchers with no-cost access to Metabolon’s industry-leading metabolomics platform, scientific expertise, bioinformatics tools, and data interpretation resources.

MORRISVILLE, N.C., August 11, 2026 — Metabolon, Inc., the global leader in metabolomics solutions advancing life sciences research, diagnostic, therapeutic, and precision medicine applications, today announced the launch of the Metabolon Peak Science Grant Program, a competitive quarterly grant designed to help researchers advance high-impact science through access to Metabolon’s industry-leading metabolomics platform, analytical services, bioinformatics tools, data resources, and scientific expertise.

The Peak Science Grant Program reflects Metabolon’s commitment to accelerating transformative research by empowering investigators with high-quality metabolomics data and expert scientific guidance. Each quarter, Metabolon will select three finalists and award one winning project a fully funded metabolomics study.

The program is open to researchers seeking to use metabolomics to uncover new biology, strengthen an existing study, support translational discovery, generate preliminary data for future funding, or inform scientific decision-making. Applications are encouraged from researchers in academia and industry working across disease biology, translational research, population health, microbiome research, nutrition, environmental health, and related life science disciplines.

“Metabolomics has the power to reveal biology that other technologies can miss, providing a direct view into phenotype, function, and biochemical activity,” said Rohan Hastie, CEO of Metabolon. “Through the Peak Science Grant Program, we are helping researchers bring metabolomics into promising studies that can advance discovery, strengthen scientific decision-making, and open new paths for understanding health, disease, and biological systems.”

The selected project will receive a Metabolon-supported metabolomics study at no cost. The grant award includes consultation with Metabolon scientists on study design and statistical power, metabolomics analysis of up to 100 qualified samples, comprehensive project deliverables including a standard interpretation report and supporting datasets, access to the Metabolon Integrated Bioinformatics Platform for data analysis and visualization, and scientific guidance for biological interpretation and downstream data analysis.

Finalists will be invited to discuss their proposed project with Metabolon’s scientific and business development representatives to confirm feasibility, timelines, sample requirements, and other study details before the final grant award winner is selected. Finalists will also receive a 10% credit for a future Metabolon project.

Applications will be evaluated based on scientific impact, feasibility, and innovation. Reviewers will consider whether the proposed study has the potential to uncover new insights, advance biological understanding, improve scientific decision-making, and demonstrate a creative or novel use of metabolomics. All applications will be reviewed by a panel of senior scientific leaders from Metabolon’s R&D, lab operations, and Discovery & Translational Sciences teams.

The submission deadline for the current quarter is September 30, 2026, and for the fourth quarter, December 31, 2026. Applications will be reviewed promptly following each submission deadline.

To learn more or apply for the Metabolon Peak Science Grant Program, please visit https://www.metabolon.com/metabolomics-grant/

About Metabolomics

Metabolomics, the large-scale study of all small molecules in a biological system, is the only omics technology that provides a complete current-state functional readout of a biological system. Metabolomics helps researchers see beyond individual genetic variation, capturing the combined impact of genetic and external factors, such as drugs, diet, lifestyle, and the microbiome, on human health. By measuring thousands of discrete chemical signals that form biological pathways in the body, metabolomics can reveal important biomarkers, enabling a better understanding of a drug’s mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to therapy.

About Metabolon

Metabolon, Inc. is the global leader in metabolomics, with a mission to deliver biochemical data and insights that expand and accelerate the impact of life sciences research and complement other ‘omics’ technologies. With more than 25 years, 15,000+ projects, 4,000+ publications, and ISO 9001:2015, CLIA, and CAP certifications, Metabolon has developed industry-leading scientific, technological, and bioinformatics techniques. Metabolon’s Global Discovery Panel is powered by the world’s largest proprietary metabolomics reference library. Metabolon’s industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and enhancing development success. The company offers scalable, customizable multiomics solutions, including metabolomics and lipidomics, that support customer needs from discovery through clinical trials and product life-cycle management. For more information, please visit www.metabolon.com/ and follow us on LinkedIn and X.

Media Inquiries

Sean Iverson
VP, Global Marketing
mailto:siverson@metabolon.com

Talk with an expert
Request a quote for our services, get more information on sample types and handling procedures, request a letter of support, or submit a question about how metabolomics can advance your research.

Contact Metabolon

Corporate Headquarters
617 Davis Drive, Suite 100
Morrisville, NC 27560

Mailing Address
P.O. Box 110407
Research Triangle Park, NC 27709

Phone
+1 (919) 572-1711

Fax
+1 (919) 572-1721

International Headquarters
Metabolon GmbH
Zeppelinstraße 3
85399 Hallbergmoos
Germany

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.